Long-Term Neutralizing Antibody Titers After BNT162b2 Vaccination in Hemodialysis Patients

Kidney Int Rep. 2023 Jun 17;8(9):1883-1886. doi: 10.1016/j.ekir.2023.06.008. eCollection 2023 Sep.

Takahiro Takazono^{1

2}, Mya Myat Ngwe Tun^{3

4

5}, Satoshi Funakoshi⁶, Shimpei Morimoto^{7

8}, Kenji Ota⁹, Kenta Torigoe¹⁰, Shinichi Abe¹⁰, Kumiko Muta¹⁰, Yuya Ito², Nobuyuki Ashizawa², Mineaki Kitamura¹⁰, Kazuaki Takeda², Naoki Iwanaga², Shotaro Ide², Masato Tashiro¹, Naoki Hosogaya⁸, Tomoya Nishino¹⁰, Katsunori Yanagihara⁹, Koichi Izumikawa¹, Kouichi Morita^{3

5}, Hiroshi Mukae²

¹ Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
² Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.
³ Department of Virology, Institute of Tropical Medicine and Leading Program, Nagasaki University, Nagasaki, Japan.
⁴ Department of Tropical Viral Vaccine Development, Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan.
⁵ DEJIMA Infectious Disease Research Alliance, Nagasaki University, Nagasaki, Japan.
⁶ Nagasaki Renal Center, Nagasaki, Japan.
⁷ Innovation Platform and Office for Precision Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
⁸ Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan.
⁹ Department of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.
¹⁰ Department of Nephrology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

No abstract available

Keywords: BNT162b2 vaccine; COVID-19; SARS-CoV-2; cut-off; hemodialysis; neutralization antibody.